Stable production of recombinant SARS-CoV-2 receptor-binding domain in  mammalian cells with co-expression of a fluorescent reporter and its  validation as antigenic target for COVID-19 serology testing

Corrales Aguilar, Eugenia; Arias Arias, Jorge Luis; Molina Castro, Silvia Elena; Monturiol Gross, Laura; Lomonte, Bruno

Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing

dc.creator	Corrales Aguilar, Eugenia
dc.creator	Arias Arias, Jorge Luis
dc.creator	Molina Castro, Silvia Elena
dc.creator	Monturiol Gross, Laura
dc.creator	Lomonte, Bruno
dc.date.accessioned	2023-05-12T20:19:53Z
dc.date.available	2023-02-07T20:05:43Z
dc.date.available	2023-05-12T20:19:53Z
dc.date.issued	2023-01
dc.description.abstract	SARS-CoV-2 receptor binding domain (RBD) recognizes the angiotensin converting enzyme 2 (ACE2) receptor in host cells that enables infection. Due to its antigenic specificity, RBD production is important for development of serological assays. Here we have established a system for stable RBD production in HEK 293T mammalian cells that simultaneously express the recombinant fluorescent protein dTomato, which enables kinetic monitoring of RBD expression by fluorescence microscopy. In addition, we have validated the use of this recombinant RBD in an ELISA assay for the detection of anti-RBD antibodies in serum samples of COVID-19 convalescent patients. Recombinant RBD generated using this approach can be useful for generation of antibody-based therapeutics against SARS-CoV-2, as well serological assays aimed to test antibody responses to this relevant virus.	es_ES
dc.description.procedence	UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET)	es_ES
dc.description.procedence	UCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiología	es_ES
dc.description.sponsorship	Universidad de Costa Rica/[741-C1-015]/UCR/Costa Rica	es_ES
dc.description.sponsorship	Universidad de Costa Rica/[803-C0-344]/UCR/Costa Rica	es_ES
dc.description.sponsorship	Universidad de Costa Rica/[803-C1-509]/UCR/Costa Rica	es_ES
dc.identifier.citation	https://doi.org/10.1016/j.btre.2022.e00780	es_ES
dc.identifier.codproyecto	741-C1-015
dc.identifier.codproyecto	803-C0-344
dc.identifier.codproyecto	803-C1-509
dc.identifier.doi	10.1016/j.btre.2022.e00780
dc.identifier.issn	2215-017X
dc.identifier.uri	https://hdl.handle.net/10669/88167.2
dc.language.iso	eng	es_ES
dc.rights	Attribution-NoDerivatives 4.0 Internacional	*
dc.source	Biotechnology reports 37 (2023)	es_ES
dc.subject	SARS-CoV-2	es_ES
dc.subject	Recombinant RBD expression	es_ES
dc.subject	Fluorescent protein	es_ES
dc.subject	Mammalian cells	es_ES
dc.subject	COVID-19	es_ES
dc.title	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing	es_ES
dc.type	artículo original	es_ES